Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder

Takaharu Azekawa, Shizuko Ohashi, Akira ItamiShioiri Mental Clinic, Yokosuka-shi, Kanagawa-ken, JapanBackground: Effectiveness of a drug is a key concept dependent on efficacy, safety, and tolerability. Time to discontinuation of treatment is also representative of effectiveness. We investigated dif...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Azekawa T, Ohashi S, Itami A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/32095dcd9ded4fbb999301bcb15c1c8a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:32095dcd9ded4fbb999301bcb15c1c8a
record_format	dspace
spelling	oai:doaj.org-article:32095dcd9ded4fbb999301bcb15c1c8a2021-12-02T04:17:07ZComparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder1176-63281178-2021https://doaj.org/article/32095dcd9ded4fbb999301bcb15c1c8a2011-11-01T00:00:00Zhttp://www.dovepress.com/comparative-study-of-treatment-continuation-using-second-generation-an-a8686https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Takaharu Azekawa, Shizuko Ohashi, Akira ItamiShioiri Mental Clinic, Yokosuka-shi, Kanagawa-ken, JapanBackground: Effectiveness of a drug is a key concept dependent on efficacy, safety, and tolerability. Time to discontinuation of treatment is also representative of effectiveness. We investigated differences in treatment discontinuation among newly started second-generation antipsychotics in the clinical setting.Methods: Using a retrospective cohort study design, we screened all outpatients (n = 7936) who visited the Shioiri Mental Clinic between July 1, 2008 and June 30, 2010. We identified a cohort of patients (n = 703) diagnosed with schizophrenia or schizoaffective disorder and calculated the time to discontinuation of each second-generation antipsychotic.Results: Of the 703 patients, 149 were newly treated with aripiprazole, 67 with blonanserin, 95 with olanzapine, 36 with quetiapine, 74 with perospirone, and 120 with risperidone. The time to discontinuation for all causes was significantly longer for aripiprazole than for blonanserin, olanzapine, and risperidone. In addition, aripiprazole tended to be continued for longer than quetiapine and perospirone, but these differences were not significant.Conclusion: Aripiprazole may be considered the best available option for long-term treatment of patients with schizophrenia or schizoaffective disorder.Keywords: retrospective study, second-generation antipsychotics, effectiveness, treatment continuation, schizophrenia, aripiprazoleAzekawa TOhashi SItami ADove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2011, Iss Issue 1, Pp 691-695 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Azekawa T Ohashi S Itami A Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
description	Takaharu Azekawa, Shizuko Ohashi, Akira ItamiShioiri Mental Clinic, Yokosuka-shi, Kanagawa-ken, JapanBackground: Effectiveness of a drug is a key concept dependent on efficacy, safety, and tolerability. Time to discontinuation of treatment is also representative of effectiveness. We investigated differences in treatment discontinuation among newly started second-generation antipsychotics in the clinical setting.Methods: Using a retrospective cohort study design, we screened all outpatients (n = 7936) who visited the Shioiri Mental Clinic between July 1, 2008 and June 30, 2010. We identified a cohort of patients (n = 703) diagnosed with schizophrenia or schizoaffective disorder and calculated the time to discontinuation of each second-generation antipsychotic.Results: Of the 703 patients, 149 were newly treated with aripiprazole, 67 with blonanserin, 95 with olanzapine, 36 with quetiapine, 74 with perospirone, and 120 with risperidone. The time to discontinuation for all causes was significantly longer for aripiprazole than for blonanserin, olanzapine, and risperidone. In addition, aripiprazole tended to be continued for longer than quetiapine and perospirone, but these differences were not significant.Conclusion: Aripiprazole may be considered the best available option for long-term treatment of patients with schizophrenia or schizoaffective disorder.Keywords: retrospective study, second-generation antipsychotics, effectiveness, treatment continuation, schizophrenia, aripiprazole
format	article
author	Azekawa T Ohashi S Itami A
author_facet	Azekawa T Ohashi S Itami A
author_sort	Azekawa T
title	Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
title_short	Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
title_full	Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
title_fullStr	Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
title_full_unstemmed	Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
title_sort	comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/32095dcd9ded4fbb999301bcb15c1c8a
work_keys_str_mv	AT azekawat comparativestudyoftreatmentcontinuationusingsecondgenerationantipsychoticsinpatientswithschizophreniaorschizoaffectivedisorder AT ohashis comparativestudyoftreatmentcontinuationusingsecondgenerationantipsychoticsinpatientswithschizophreniaorschizoaffectivedisorder AT itamia comparativestudyoftreatmentcontinuationusingsecondgenerationantipsychoticsinpatientswithschizophreniaorschizoaffectivedisorder
_version_	1718401303198040064

Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder

Ejemplares similares